MLTX (MoonLake Immunotherapeutics) Stock Financials & Earnings

MLTXMoonLake Immunotherapeutics

Mkt Cap$1B

Healthcare·Biotechnology·🇨🇭 Switzerland·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$227M

EPS (TTM)-$3.53

Free Cash Flow (TTM)-$196M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$13M
Q2 23	$0	$0	-$13M
Q3 23	$0	$0	-$13M
Q4 23	$0	$0	-$15M
Q1 24	$0	$0	-$20M
Q2 24	$0	$0	-$31M
Q3 24	$0	-$33K	-$43M
Q4 24	$0	$0	-$50M
Q1 25	$0	$0	-$47M
Q2 25	$0	-$742K	-$61M
Q3 25	$0	-$745K	-$71M
Q4 25	$0	-$751K	-$65M

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$7M	$6M	—
Q2 23	$9M	$4M	—
Q3 23	$8M	$5M	—
Q4 23	$8M	$7M	—
Q1 24	$13M	$7M	—
Q2 24	$24M	$7M	—
Q3 24	$36M	—	$7M
Q4 24	$40M	$9M	—
Q1 25	$36M	$11M	—
Q2 25	$49M	$11M	—
Q3 25	$60M	—	$11M
Q4 25	$57M	$9M	—

Revenue Segments

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$50M	$13M	$63M
Q2 23	$502M	$0	$502M
Q3 23	$318M	$178M	$496M
Q4 23	$451M	$60M	$511M
Q1 24	$458M	$89M	$547M
Q2 24	$343M	$177M	$520M
Q3 24	$376M	$118M	$494M
Q4 24	$180M	$268M	$448M
Q1 25	$272M	$209M	$480M
Q2 25	$307M	$118M	$425M
Q3 25	$351M	$30M	$380M
Q4 25	$335M	$59M	$394M

Shares Outstanding

Revenue Per Employee

Revenue / Employee